Previous 10 | Next 10 |
Quick Take Checkmate Pharmaceuticals ( CMPI ) has filed to raise $75 million in an IPO of its common stock, according to an S-1 registration statement . The company is a clinical stage biopharma advancing a drug treatment candidate for melanoma and head & neck cancer. CMPI has produ...
Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that it has been added to the Russell 2000® index. This addition was effective June 26, 2020. “We are pleased that...
Poster presentation of pharmacodynamic and safety data of cavrotolimod (AST-008) from Exicure’s ongoing Phase 1b/2 clinical trial in solid tumor patients Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SN...
Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that Dr. David Giljohann, Chief Executive Officer of Exicure, will present a corporate update at the virtual 2020 BMO Prescriptio...
Exicure (NASDAQ: XCUR ) doses first patient in the Phase 2 dose expansion stage of the cavrotolimod (AST-008) Phase 1b/2 clinical trial. More news on: Exicure, Inc., Healthcare stocks news, Read more ...
Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today the dosing of the first patient enrolled in the Phase 2 dose expansion stage of the cavrotolimod (AST-008) Phase 1b/2 clinical tr...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 160 weeks of public selections as part of this ongoing live forward-testing resea...
Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that Dr. David Giljohann, Chief Executive Officer of Exicure, will present at the virtual Jefferies 2020 Healthcare Conference on...
Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that it has appointed Douglas E. Feltner, M.D. as its Chief Medical Officer effective May 18 th , 2020. Dr. Feltner joins Exicure ...
Poster presentation will show updated pharmacodynamic and safety data of AST-008 from Exicure’s ongoing Phase 1b/2 study Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, will prese...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
-3.60% Change Percent:
Exicure Inc. Company Name:
XCUR Stock Symbol:
OTCMKTS Market:
Exicure Inc. Website:
A look at the top 10 most actives in the United States Agape ATP Corporation (ATPC) rose 112.1% to $0.3033 on volume of 62,336,784 shares Warrantee Inc. (WRNT) rose 27.8% to $0.372 on volume of 55,635,565 shares Adial Pharmaceuticals Inc (ADIL) rose 110.3% to $2.2295 on volume of 54,549,4...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspe...